09/07/2020
The Polish Viofor system has become the first medical device with a clinically documented effect on the treatment of recurrent upper respiratory tract infections.
"The lack of a drug that is 100% effective in combating the COVID-19 pandemic has forced us to seek potential support from medical devices in the fight against upper respiratory tract infections caused by viruses and bacteria (bacterial superinfections often arise after viral infections of the upper respiratory tract).
Referring to the calls of the Minister of Health and the European Commission referring to mutual cooperation and intensified search for direct or indirect treatment methods for patients suffering from COVID-19, the scientific library of Viofor products in the area of medical devices was reviewed.
The review identified publications from clinical and in vitro preclinical studies devoted to immune system enhancement through magnetostimulation.
Its positive immunocorrective effect was described 15 years ago in Pediatrics Med Rodz. 2005, 1 (1): 78-83 and Central European Journal of Immunology, 2005, Vol.30, Supplement I, item 64.
Additionally, other studies of over 600 small patients struggling with recurrent upper respiratory tract infections were analyzed.
During 12 months of therapy conducted at the IMW Pediatrics Clinic in cooperation with the Laboratory of Immunology of the Microwave Protection Institute of the Military Institute of Hygiene and Epidemiology in Warsaw, a decrease in the number of exacerbations of upper respiratory tract infections in children was observed, as well as their lighter course.
Favorable results of the use of magnetostimulation in the treatment of secondary immune deficiencies in children are the result of stimulation of the thymus-dependent process of T lymphocyte maturation and supplementation of deficiencies of this cell population.
The immunocorrective effect occurs by reducing the concentration of pro-inflammatory cytokines: TNF-α, IL-8, IL-10, Il-1beta, thus improving the efficiency of the immune system."
Dr n. farm. Leszek Borkowski Polski wyrób medyczny wsparciem dla farmakologii w COVID-19 Dr Leszek Borkowski 2020-06-21 20:32 Polski system Viofor został pierwszym wyrobem medycznym o udokumentowanym klinicznie wpływie na leczenie nawracających infekcji górnych dróg oddechowych. Brak do dzisia...